Strategic Alliances with PharmaJet
Many leading pharmaceutical, biotechnology, and academic institutions have formed strategic alliances with PharmaJet to use our needle-free injection systems to enhance the delivery of their injected medicines and vaccines.
Needle-free delivery provides a safe and often, more effective alternative to traditional injection techniques. We have needle-free devices for intradermal (ID), subcutaneous (SC), and intramuscular (IM) delivery in 0.5 ml and 0.1 mL dose volumes. Variable dose devices are in late stages of development.
Click on image to enlarge
Our Needle-free Injection Systems Effectively Deliver
✓ Low and high viscosity medicines
✓ Proteins and peptides
✓ Specialty drug therapies
✓ Nucleic acid-based vaccines and therapeutics
Tropis (ID) Clinical Pipeline
2 approved products
11 ongoing clinical studies
54 ongoing preclinical studies
Infectious Disease
INFLUENZA
Vaccine
Phase 1 Phase 2 Phase 3
Approval
Partner
Split egg-derived
Ph 1 Ph 2 Ph 3
HPV
Vaccine
Phase 1 Phase 2 Phase 3
Approval
Partner
VLP
Ph 1 Ph 2 Ph 3
COVID-19
Vaccine
Phase 1 Phase 2 Phase 3
Approval
Partner
samRNA
Ph 1 Ph 2 Ph 3
EUA in India
DNA
Ph 1 Ph 2 Ph 3
EUA in India
DNA
Ph 1 Ph 2 Ph 3
DNA
Ph 1 Ph 2 Ph 3
DNA
Ph 1 Ph 2 Ph 3
DNA
Ph 1 Ph 2 Ph 3
VEEV
Vaccine
Phase 1 Phase 2 Phase 3
Approval
Partner
DNA
Ph 1 Ph 2 Ph 3
ONCOLOGY
Breast Cancer
Vaccine
Phase 1 Phase 2 Phase 3
Approval
Partner
DNA
Ph 1 Ph 2 Ph 3
HPV
Vaccine
Phase 1 Phase 2 Phase 3
Approval
Partner
DNA
Ph 1 Ph 2 Ph 3
Lymphoma
Vaccine
Phase 1 Phase 2 Phase 3
Approval
Partner
DNA
Ph 1 Ph 2 Ph 3
OTHER APPLICATIONS
Alzheimer's
Vaccine
Phase 1 Phase 2 Phase 3
Approval
Partner
DNA
Ph 1 Ph 2 Ph 3
Stratis (IM/SC) Clinical Pipeline
1 approved products
19 ongoing clinical studies
32 ongoing preclinical studies
INFECTIOUS DISEASE
Influenza
Vaccine
Phase 1 Phase 2 Phase 3
Approval
Partner
Split-egg derived
Ph 1 Ph 2 Ph 3
On label for Afluria
HPV
Vaccine
Phase 1 Phase 2 Phase 3
Approval
Partner
VLP
Ph 1 Ph 2 Ph 3
Hantaan
Vaccine
Phase 1 Phase 2 Phase 3
Approval
Partner
DNA
Ph 1 Ph 2 Ph 3
COVID-19
Vaccine
Phase 1 Phase 2 Phase 3
Approval
Partner
DNA
Ph 1 Ph 2 Ph 3
DNA
Ph 1 Ph 2 Ph 3
DNA
Ph 1 Ph 2 Ph 3
DNA
Ph 1 Ph 2 Ph 3
HIV
Vaccine
Phase 1 Phase 2 Phase 3
Approval
Partner
DNA
Ph 1 Ph 2 Ph 3
HPV/HIV
Vaccine
Phase 1 Phase 2 Phase 3
Approval
Partner
DNA
Ph 1 Ph 2 Ph 3
VEEV
Vaccine
Phase 1 Phase 2 Phase 3
Approval
Partner
DNA
Ph 1 Ph 2 Ph 3
ONCOLOGY
Cervical Cancer
Vaccine
Phase 1 Phase 2 Phase 3
Approval
Partner
DNA
Ph 1 Ph 2 Ph 3
DNA
Ph 1 Ph 2 Ph 3
Head and Neck
Vaccine
Phase 1 Phase 2 Phase 3
Approval
Partner
DNA (neoantigen)
Ph 1 Ph 2 Ph 3
Metastic Solid Tumors
Vaccine
Phase 1 Phase 2 Phase 3
Approval
Partner
DNA (neoantigen)
Ph 1 Ph 2 Ph 3
DNA (neoantigen)
Ph 1 Ph 2 Ph 3
Melanoma
Vaccine
Phase 1 Phase 2 Phase 3
Approval
Partner
DNA (gp100 and TRP-2)
Ph 1 Ph 2 Ph 3
DNA (neoantigen)
Ph 1 Ph 2 Ph 3
Merkel Cell Carcinoma
Vaccine
Phase 1 Phase 2 Phase 3
Approval
Partner
DNA
Ph 1 Ph 2 Ph 3
Fast Track
HPV
Vaccine
Phase 1 Phase 2 Phase 3
Approval
Partner
DNA
Ph 1 Ph 2 Ph 3
OTHER APPLICATIONS
Bleeding DIsorders
Vaccine
Phase 1 Phase 2 Phase 3
Approval
Partner
DNA
Ph 1 Ph 2 Ph 3
PharmaJet Vaccine Partnerships
We are interested in collaboration opportunities with partners where our technology can enhance the delivery of injectables in areas such as biologics, vaccines, small molecules, and other therapeutic technology platforms.
PharmaJet currently has active collaborations with a wide variety of partners including emerging biotechnology companies, established pharmaceutical companies, Armed Forces/DoD (Department of Defense), Federal Agencies, among others.
